Physician

Mark E Willcox, M.D.

According to 2025 Medicare claims, Mark Willcox, M.D. (NPI: 1336395599) practices cardiac electrophysiology in the Anchorage, AK market, with the plurality of this provider's patient population coming from Anchorage, AK. This provider's primary affiliated billing organization is ALASKA HEART INSTITUTE (NPI: 1992744114; TIN: 92-0165692) and primary practice location at 99508-4615. Willcox is affiliated with the Envoy Integrated Health ACO, LLC (ACO ID: A5392), participating under the MSSP model.

Willcox's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 969 traditional Medicare patients, billed 2,379 HCPCS/CPT codes, and received $363,969 in Medicare payments. The top billing code was 93656 (Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation). Part D data shows 847 prescription claims across 225 beneficiaries totaling $450,968 in drug costs, led by Eliquis (Apixaban). Open Payments data shows 19 records totaling $4,292. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $4,227 to $450,968. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	238	501	$81,274
2017	788	2,454	$297,551
2018	991	2,593	$360,587
2019	674	2,138	$362,291
2020	596	1,730	$354,193
2021	690	1,980	$403,131
2022	658	1,724	$326,115
2023	835	1,856	$294,107
2024	969	2,379	$363,969

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	32	96	$4,227
2016	50	125	$21,029
2017	80	499	$91,661
2018	96	485	$140,323
2019	205	1,008	$464,341
2020	231	1,177	$501,135
2021	233	983	$472,355
2022	236	992	$505,190
2023	229	945	$511,942
2024	225	847	$450,968

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93656	Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation	67	67	$925
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	144	144	$153
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	155	175	$121
93623	Programming of heart rhythm stimulation after drug infusion	78	78	$64
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	534	608	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	227	15,495	$293,226
Xarelto	Rivaroxaban	56	4,620	$85,177
Multaq	Dronedarone Hcl	17	1,327	$33,205
Entresto	Sacubitril/Valsartan	32	888	$17,666
Metoprolol Succinate	Metoprolol Succinate	111	9,619	$3,008

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	17	$515	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$3,777	Medtronic, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark E. Willcox, M.D.?

Tedicare shows public-source Medicare data for Mark E. Willcox, M.D. (NPI 1336395599), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark E. Willcox, M.D. have ACO affiliation data?

Mark E. Willcox, M.D. is shown with ACO affiliation data for Envoy Integrated Health ACO, LLC (MSSP, ACO ID A5392).

What billing organization is linked to Mark E. Willcox, M.D.?

Mark E. Willcox, M.D. is linked to ALASKA HEART INSTITUTE (billing NPI 1992744114) in the available physician profile data.

Does Mark E. Willcox, M.D. have Open Payments data?

Mark E. Willcox, M.D. has 19 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.